Nitric oxide in sepsis and endotoxaemia

Area of Science:

• Biochemistry
• Pathophysiology
• Pharmacology

Background:

• Nitric oxide (NO) is a key vasoactive substance produced by nitric oxide synthase (NOS) enzymes.
• Physiological NO is generated by constitutive NOS (nNOS, eNOS), while sepsis induces iNOS, leading to excessive NO production.
• This excessive NO contributes to vasoplegia, myocardial depression, and enhanced bacterial lysis in sepsis.

Purpose of the Study:

• To investigate the effects of modulating nitric oxide pathways in sepsis.
• To evaluate the therapeutic potential of targeting inducible nitric oxide synthase (iNOS).
• To assess the impact of NO modulation on cardiovascular function and survival in sepsis models.

Main Methods:

• Examined the cardiovascular and physiological effects of inhibiting the L-arginine NO pathway.
• Investigated selective inhibitors targeting iNOS, such as L-canavanine, in experimental animals.
• Reviewed studies involving iNOS knock-out mice to understand the role of iNOS-derived NO.

Main Results:

• Inhibitors of the L-arginine NO pathway alleviated some cardiovascular effects in sepsis but caused detrimental outcomes in patients.
• Selective iNOS inhibition with L-canavanine showed promise in animal models, protecting endothelial cells and improving vascular responsiveness.
• Studies in iNOS knock-out mice did not conclusively support improved survival by eliminating iNOS-derived NO.

Conclusions:

• Modulating nitric oxide pathways in sepsis presents a complex therapeutic challenge.
• While selective iNOS inhibition shows potential in preclinical models, its clinical efficacy in human sepsis remains unproven.
• Further research is needed to clarify the role of different NOS isoforms in sepsis and guide therapeutic strategies.